Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Cloughesy

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Plos One|October 29, 2014
Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomasAnne L Baldock, Sunyoung Ahn, Russell Rockne, et al.
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2022
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent GlioblastomaLakshmi Nayak, Nathan Standifer, Jorg Dietrich, et al.
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Journal of the National Cancer Institute|September 5, 2012
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomasArthur P Chou, Reshmi Chowdhury, Sichen Li, et al.
Brain Pathology (Zurich, Switzerland)|February 27, 2013
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastomaJoanna J Phillips, Derick Aranda, David W Ellison, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of originAlbert Lai, Samir Kharbanda, Whitney B Pope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Plos One|October 29, 2014
Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomasAnne L Baldock, Sunyoung Ahn, Russell Rockne, et al.
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2022
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent GlioblastomaLakshmi Nayak, Nathan Standifer, Jorg Dietrich, et al.
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Journal of the National Cancer Institute|September 5, 2012
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomasArthur P Chou, Reshmi Chowdhury, Sichen Li, et al.
Brain Pathology (Zurich, Switzerland)|February 27, 2013
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastomaJoanna J Phillips, Derick Aranda, David W Ellison, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of originAlbert Lai, Samir Kharbanda, Whitney B Pope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Pageof 10